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Abstract
Objective: The purpose of this study was to assess the frequency of persistent drug-induced movement disorders namely,
tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia in a representative sample of long-stay patients with
chronic severe mental illness.
Method: Naturalistic study of 209, mainly white, antipsychotic-treated patients, mostly diagnosed with psychotic disorder.
Of this group, the same rater examined 194 patients at least two times over a 4-year period, with a mean follow-up time of
1.1 years, with validated scales for TD, parkinsonism, akathisia, and tardive dystonia.
Results: The frequencies of persistent movement disorders in the sample were 28.4% for TD, 56.2% for parkinsonism, 4.6%
for akathisia and 5.7% for tardive dystonia. Two-thirds of the participants displayed at least one type of persistent
movement disorder.
Conclusions: Persistent movement disorder continues to be the norm for long-stay patients with chronic mental illness and
long-term antipsychotic treatment. Measures are required to remedy this situation.
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Introduction
Antipsychotics remain the cornerstone of treatment in psychotic
disorder. However, they may induce several side effects, one of
which is movement disorder. Antipsychotic-induced movement
disorder constitutes a major reason for non-compliance, resulting
in an increased risk of psychotic relapse [1–3]. In addition, a meta-
analysis [4] and two recent studies showed a higher mortality in
patients with tardive dyskinesia (TD) [5,6].
Antipsychotic-induced movement disorders [7,8] can be divided
in acute syndromes such as parkinsonism and akathisia, that occur
within days or weeks after starting an antipsychotic, or after
increasing the dose, and tardive syndromes, such as TD and tardive
dystonia, that develop after months or years of antipsychotic
treatment. In patients on long-term treatment with antipsychotics,
combinations of acute and tardive syndromes may also occur.
Although second generation antipsychotics (SGAs) may be
associated with a lower incidence rate of movement disorder, these
medications nevertheless still carry risk [9–18]. In patients on long-
term treatment with first generation antipsychotics (FGAs), the
reported prevalence of antipsychotic-induced movement disorders
was around 50 to 75% [19,20]. Eleven long-term studies with
SGAs (except clozapine) showed a reduced risk of drug-induced
movement disorder, but not their expected disappearance [21].
These studies had several limitations such as lack of equivalent
dosage of haloperidol in the control arm, high drop-out rates, short
study duration and unreliable measurement of movement
disorder. Three large, non-commercially funded trials published
in the last five years found differences in the incidence of
parkinsonism and akathisia, but no clear differences in the
incidence of TD in a comparison between FGAs and SGAs
(CATIE, Cutlass and EUFEST trial) [1,9,15,17]. However, these
studies also had methodological limitations such as a relatively
short time to detect TD (around one year), high drop-out rates,
and, in the Cutlass trial, many patients in the FGA group used
sulpiride which has a lower incidence of movement disorder and is
classified by some researchers as an SGA. A recent prospective
cohort study with TD as primary outcome found no significant
difference in the incidence of TD between patients taking FGAs
and SGAs [22]. Leucht and colleagues [23] demonstrated that
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particular properties. Furthermore, from a global perspective, the
three antipsychotic drugs listed in the most recent (Index 2011)
World Health Organization Model List of Essential Medicines are
FGAs, namely chlorpromazine, fluphenazine and haloperidol
(http://www.who.int/medicines/en).
Populations most at risk are those that are chronically exposed
to antipsychotics, particularly when residing in hospital settings,
where compliance likely is high and polypharmacy is common,
further increasing risk for movement disorder [24]. Although long-
stay settings are not mainstream, they remain a reality for a
considerable number of patients with severe and chronic mental
illness [25], and can be extended to the population in supervised
residences in the community, where intake of medication often is
similarly supervised. One retrospective survey reported existence
of an antipsychotic polypharmacy regimen in 27.5% of the
discharged patients with schizophrenia, such as concurrent use of
FGAs and SGAs, in a tertiary psychiatric setting [26]. Broekema
and colleagues [27] reported that the combination of SGAs and
FGAs and/or anticholinergics constituted common practice in
several European psychiatric hospitals. Routine cross-sectional
data may not be suitable for the examination of rates of movement
disorder in vulnerable populations with chronic mental illness, as
drug-induced movement disorders fluctuate over time and remain
underdiagnosed by both psychiatrists and neurologists [28–31].
For these reasons, a systematic and prospective assessment of
movement disorder in a representative population of patients with
long-term exposure to antipsychotics was used to examine the
hypothesis that movement disorders remain highly prevalent in
vulnerable populations.
Methods
Ethics statement
The protocol was approved by the standing Institutional Review
Board, ‘Medisch-ethische Toetsingscommissie Instellingen Gees-
telijke Gezondheidszorg’ (Review Board for Human Research in
Psychiatry), the Netherlands [protocol number 377].
Written informed consent was obtained from each patient; consent
obtained from the next of kin was neither necessary nor recommended
by the Review Board for Human Research in Psychiatry.
Subjects
A 4-year prospective naturalistic study (July 2003–May 2007) was
conducted in order to determine the frequency of TD, parkinsonism,
akathisia and tardive dystonia in 209 patients with chronic mental illness.
To this end, a cohort was drawn from a general psychiatric hospital
(GGZ Centraal, Amersfoort, the Netherlands). Inclusion criteria were:
minimum age of 18 years and cumulative exposure to antipsychotics for
at least 1 year. Exclusion criteria were: history of neurological disorders
impacting on motor function. The cohort was representative of the
population of patients with the most severe chronic mental illness
requiring long-stay care, given that the hospital serves an epidemiological
catchment area, is the only institute providing this type of care and
patients were approached using a comprehensive list of all in-patient.
Of the patients assessed at baseline (N=207) 93.7% (n=194)
had one follow-up and 59.4% (n=123) had two follow-up
assessments. Loss to follow-up was due to patients who were
difficult to trace after leaving hospital, as well as patients dying or
patients refusing assessment after inclusion.
Assessment
Patients were examined by a trained psychiatrist (PRB), using a
standard protocol, described by van Harten and colleagues [32].
Patients were barefooted and seated in a chair without armrests.
The researcher asked detailed questions about (i) use of chewing
gum or candy at the moment of assessment as well as (ill-fitting)
dentures, as both may be misdiagnosed as orofacial movement
disorders, and (ii) subjective akathisia. The patient performed
different tasks to assess the existence of movement disorders and to
provoke abnormal movements. Thus, the following positions were
adopted in succession: resting arms on the lap in different
positions, arms hanging aside, stretching arms, making fast
alternating hand and foot movements, opening the mouth,
showing the tongue, rising from chair, and walking. Additionally,
posture, rigidity and balance were assessed. Tongue dyskinesia was
provoked by fingertip movements, and objective akathisia by
talking conversationally while the patient was standing.
Originally, in addition to the term ‘acute’, the term ‘tardive’
(delayed) was introduced to emphasize the late-onset types of
movement disorders during antipsychotic use. Yet, the definition
in the current study emphasizes their persistence, which is more
important [8,33].
Dyskinesia [34] was defined as hyperkinetic choreiform
involuntary movements which often fluctuates in severity. TD
was assessed with the Abnormal Involuntary Movement Scale
(AIMS) [35,36] and case definition was based on Schooler and
Kane criteria [37], requiring (i) the presence of moderate
dyskinesia in at least one body area or mild dyskinesia in at least
two body parts, and (ii) the absence of other conditions resulting in
abnormal involuntary movements.
Parkinsonism was assessed with the Unified Parkinson Disease
Rating Scale (UPDRS) [38]. A case definition of parkinsonism was
based on (i) ‘mild’ expression of rest-tremor or rigidity as both are
typical of parkinsonism, and (ii) if no tremor or rigidity was rated,
the cut-off point was one rating of ‘moderate’ or two ratings of
‘mild’ on items of bradykinesia and postural stability. The more
stringent criteria for items of bradykinesia and postural stability
were chosen as these symptoms may be part of psychiatric
syndromes or sedation. Besides this definition, an additional case
definition of parkinsonism was applied in accordance with the UK
Brain Bank definition, using a score of 2 in the bradykinesia items
of the motor UPDRS, and a score of 1 in the items rest tremor,
rigidity or postural instability of the motor UPDRS.
Akathisia [8] was defined as both subjective inner feelings of
restlessness and objective motor (leg) movements. A case definition
of akathisia was based on a rating of at least ‘mild’ on the global
akathisia item. Akathisia was assessed with the Barnes Akathisia
Rating Scale comprising an objective and a subjective item [39].
Dystonia was defined as a syndrome of sustained muscle
contraction, frequently causing twisting and repetitive movements
or abnormal postures [40]. Tardive dystonia was diagnosed,
following Burke’s criteria [41], if one body area attracted a rating
of at least ‘mild’ or if two or more body areas attracted a rating of
‘slight’ on the Fahn-Marsden scale [42]. As frequent eye-blinking
(rating of ‘mild’ on the item ‘eye’) has many causes, case definition
of tardive dystonia required a rating of at least ‘moderate’
(blepharospasm) when ‘eye’ was the only symptom area.
The case definition of a persistent movement disorder was based
on 2 consecutive assessments over a period of minimally 3 months,
and required that individuals met case definition criteria at two
consecutive assessments (hereafter: persistent movement disorder).
Guided by previous literature, variables possibly affecting risk
were extracted from patients’ case notes including age, sex,
diagnosis according to DSM-IV, ethnic group (classified as white
and non-white) and duration of hospitalization. At baseline and at
each follow-up assessment, current use of antipsychotic and
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outpatient pharmacy databases.
The diagnosis ‘schizophrenia’ hereafter refers to DSM-IV codes
295.30, 295.10, 295.20, 295.90, 295.60, 295.70, and other
diagnoses of ‘psychotic disorder’ to 295.40, 297.1, 298.8, 298.9.
Statistical Analyses
Frequency of persistent movement disorder was calculated in
patients with minimally two assessments. Chi-squared tests and
nonparametric trend tests were applied to categorical data.
Antipsychotic doses were converted to defined daily dose
(DDD), assigned and reviewed by researchers of the World
Health Organisation Centre of Drug Statistics Methodology
(WHO, Collaborating Centre for Drugs Statistics Methodology Available
at: http://www.whocc.no/atcddd/. Accessed December 2010). DDD
was chosen as it better reflects the observed multireceptor
involvement of antipsychotics, unlike classic chlorpromazine
(CPZ) equivalents which are based mainly on dopamine-2
receptor occupancy. In addition, DDD equivalents are updated
periodically. Anticholinergic medication was modeled as a
dichotomous variable (yes/no).
Results
Sample Characteristics
Of the 209 patients included, one patient developed a brain
tumor, another patient died after inclusion. All patients had a
history of cumulative antipsychotic intake of minimally 1 year.
Attrition was 9.8%.
Most patients were white (85.0%) and had chronic mental
illness requiring long-term admission. At baseline, the mean (SD)
age was 47.4 (12.8) years; men 46.3 (12.8) and women 49.1 (12.7)
of age. The mean (SD) age at first admission was 25.0 (8.4) years;
men 23.8 (7.6) and women 26.7 (9.3) of age at first admission. The
total duration of admission was 22.1 (13.1) years. Diagnoses
according to DSM-IV Axis I as defined above were: schizophrenia
69.6%, psychosis 5.3%, affective disorder 13.5%, other Axis I
diagnosis 6.8% and no Axis I (with a Axis II) diagnosis 4.8%.
At baseline and follow-up, antipsychotics were used by 89.3–
98.5% of the patients; FGA and SGA in 64.8–67.5% and 55.7–
61.3%, respectively; FGA only and SGA only in 33.0–37.3% and
24.6–32.8%, respectively; 28.4% used both FGA and SGA at
baseline; use of 0, 1, 2, 3 and 4 antipsychotic(s) was observed in
1.5–10.7%, 41.9–55.4%, 34.3–40.8%, 4.1–8.3% and 0.5–1.6%,
respectively; total DDD equivalent antipsychotic use was 2.3–2.5.
Frequency over period of observation
Over the period of observation (mean=1.1 years, SD=0.64), at
baseline and follow-up, the frequencies of movement disorder in
the sample were 30.4–36.6% for TD, 21.7–32.5% for orofacial
TD, 11.9–13.9% for limb truncal TD, 62.9–65.9% for parkin-
sonism, 13.8–26.3% for rest tremor, 6.6–15.0% for rigidity, 53.6–
61.0% for bradykinesia, 8.8–10.4% for akathisia and 8.1–16.0%
for dystonia. The frequency of persistent movement disorder in the
sample was 28.4% for TD, 20.1% for orofacial TD, 7.7% for limb
truncal TD, 56.2% for parkinsonism, 12.9% for rest tremor, 6.7%
for rigidity, 48.5% for bradykinesia, 4.6% for akathisia and 5.7%
for dystonia. Sixty-eight percent of the participants had at least one
type of persistent movement disorder, 43.3% had a single type of
persistent movement disorder, and 24.7% had at least 2 types of
persistent movement disorder (Table 1). Using the UK Brain Bank
definition, the frequencies of parkinsonism were 51.2–60.3% at
baseline and follow-up, whereas the frequency of persistent
parkinsonism was 53.1%.
Table 2 shows the frequency of persistent movement disorder,
by age group defined by the tertile cut-offs of the age distribution.
In the nonparametric test for trend, frequency of persistent TD,
parkinsonism and tardive dystonia increased with increasing age
(p=0.005, p=0.000 and p=0.06, respectively). Frequency of
persistent akathisia decreased significantly with increasing age
(p=0.039), such that the age group of 53 and older did not display
any akathisia. Frequency of persistent parkinsonism in accordance
with UK Brain Bank definition, by age group, was 32.3%, 56.9%
and 70.3%, respectively (p=0.000).
Frequency of persistent TD, parkinsonism, akathisia and tardive
dystonia did not differ between FGA only and SGA only, both at
baseline and at follow-up (p-values 0.506–0.898, 0.392–0.962,
0.184–0.576 and 0.424–0.916, respectively). Parkinsonism in
accordance with UK Brain Bank definition did not differ between
FGA only and SGA only, both at baseline and at follow-up (p-
values 0.705–0.929).
Discussion
This study showed that persistent movement disorder remains
highly prevalent in long-stay patients with chronic mental illness
and long-term antipsychotic treatment. The high period frequency
of 68% with at least a single drug-induced movement disorder is
even more striking given the use of strict case definition criteria
that had to be positive on at least two consecutive assessments.
Clinical relevance of these findings is suggested not only because of
the high frequency of these acute and tardive movement disorders,
but also because persistence of movement disorder seems to be the
rule. This implies that most patients on long-term antipsychotic
treatment have persistent movement disorder which make this side
effect a matter of urgent consideration.
Frequencies of TD, parkinsonism and dystonia were associated
with older age, albeit the latter at trend significance only. In
contrast, akathisia was negatively associated with older age, and
even completely absent in the oldest age group. This observation
could not be explained by dosage as a post-hoc analysis showed that
total DDD equivalent at baseline and follow-up moments were
neither strongly nor significantly associated with age (r=20.02,
p=0.76; r=20.13, p=0.08; r=20.10, p=0.27, respectively).
Furthermore, around 50% of the patients used more than one type
Table 1. Period frequency
a of persistent drug-induced
movement disorders
b,c (N=194, men=114, women=80).
Movement disorder N %
Tardive dyskinesia 55 28.4
Orofacial TD
d 39 20.1
Limb truncal TD 15 7.7
Parkinsonism 109 56.2
Rest tremor 25 12.9
Rigidity 13 6.7
Bradykinesia 94 48.5
Akathisia 9 4.6
Tardive dystonia 11 5.7
aMean period was 1.1 year (SD 0.6).
bPersistent movement disorder: 2 consecutive positive assessments with an
interval of at least 3 months.
c132 (68.0%) had at least one type of movement disorder.
dTardive dyskinesia.
doi:10.1371/journal.pone.0025588.t001
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considerable high antipsychotic dosage, as the DDD is the
assumed average daily dose for a drug used for its core [43].
Yet, frequency of movement disorder between FGA and SGA did
not differ.
We compared frequencies of parkinsonism between the UK
Brain Bank definition and ours, and found similar results at
baseline and follow-up; the same held for persistent parkinsonism.
Limitations
First, it may be hypothesized that the varying number of follow-
up assessments (from 1 to 2) in the participants may have
contributed to an unstable estimate. However, frequency of
persistent movement disorders in those with 1 and 2 follow-up
assessments were similar (data not shown). Second, the cohort in
the current study was representative of the population of patients
with the most severe chronic mental illness requiring long-stay
care, the target population for this study. Thus, results cannot be
extrapolated to the entire population of psychiatric patients
exposed to antipsychotics, in whom rates of movement disorder
may be different. Third, in the current study, the mean follow-up
time seemed sufficient (1.1 years) to detect a persistent movement
disorder because the patients were on long-term antipsychotic
treatment, i.e., were exposed for a sufficiently long period to
develop a persistent movement disorder. Although this study
cannot draw firm conclusions regarding the persistence of
movement disorders in the long run, most long-term follow-up
studies nevertheless report high persistence rates. Fourth, the
classic model of movement disorders originating from antipsy-
chotics is challenged by a large body of literature and two meta-
analyses [44,45] demonstrating higher prevalence rates of
movement disorders in patients with a diagnosis of schizophrenia.
These results provide a strong argument for the hypothesis that
movement disorders may not exclusively result from antipsychotic
treatment but also reflect a fundamental aspect of neurodevelop-
mental pathophysiology involving sensitization of dopaminergic
nigrostriatal circuits [46–49]. There is no phenomenological
difference between parkinsonism and dyskinesia related to
schizophrenia versus drug-induced parkinsonism and dyskinesia.
As a consequence, caution is required in interpreting the findings.
Future prospective studies in populations of drug-naive patients
with a first episode of psychosis before and after antipsychotic
treatment are essential to make a distinction between primary (part
of schizophrenia) and secondary (drug-induced) movement
disorder. Even so, primary symptoms may develop in the course
of schizophrenia making differentiation between primary and
secondary symptoms difficult.
Although it is not possible to differentiate between primary and
secondary movement disorders in long-stay patients, and the two
types likely often occur in combination, distinguishing between the
two types is of little consequence for treatment interventions which
often consist of lowering the dosage of the antipsychotic, switching
to an SGA (preferably clozapine), or adding an anticholinergic.
Strengths
First, all assessments were performed by a single person, who
was trained and retrained (in order to prevent ‘drift’) regularly by
the senior author (PNvH), an expert in the assessment and
diagnosis of movement disorders. Second, a naturalistic and
pragmatic design was used in a representative chronic psychiatric
population, reflecting real-life clinical practice [50], and therefore
yielding high external validity. Third, definition of persistent
movement disorder was based on 2 consecutive assessments over a
period of minimally 3 months, which is in contrast with many
previous studies in which case definition was defined cross-
sectionally. Persistent movement disorder may be a more valid
measure, as it more specifically defines the disorder category given
the continuously fluctuating nature of the phenotypes under
investigation.
The prevalence of movement disorder from previous studies, as
mentioned below, concur with the current study for TD, but they
tend to be lower for parkinsonism, and tend to be higher for
akathisia as well as for tardive dystonia. However, previous studies
do not match with the current study, given the fact that these used
cross-sectional measures and did not focus on the vulnerable
subgroup of long-stay patients in hospital.
Tardive dyskinesia
Reported prevalence rates of TD vary from 3% to 70% with a
median rate of 24%, most of the TD being mild, with higher rates
in the elderly [51]. Van Harten and colleagues [32] reported a TD
prevalence of 39.7%. A recent meta-analysis concluded that age
was a likely, although not quite conclusive, risk factor for TD [52].
Other risk factors have been suggested, but with little meta-
analytic support [52].
Parkinsonism
In the study by Modestin and colleagues [47] the prevalence of
parkinsonism in 1995 and 2003/4 was 17% and 29%, respective-
ly. Janno and colleagues [19] estimated the prevalence of
parkinsonism at 23.2% and 72.7%, according to DSM-IV criteria
and Simpson-Angus Scale criteria, respectively. Van Harten and
colleagues [32] reported a parkinsonism prevalence of 36.1%.
Older age may be a risk factors for parkinsonism [7], but other
studies showed a higher risk in younger patients [53,54].
Table 2. Period frequency
a of persistent drug-induced movement disorder
b in 194 patients, by tertile age group.
Age (years)
c
Movement disorder (%) #40 (n=65) 41–52 (n=65) $53 (n=64) z
c p
Tardive dyskinesia (n=55) 15.4 32.3 37.5 2.78 0.005
Parkinsonism (n=109) 40.0 49.2 79.7 4.52 0.000
Akathisia (n=9) 7.7 6.2 0.0 22.07 0.039
Tardive dystonia (n=11) 1.5 6.2 9.4 1.92 0.055
aMean period was 1.1 year (SD 0.6).
bPersistent movement disorder: 2 consecutive positive assessments with an interval of at least 3 months.
cNonparametric test for trend across ordered groups (extension of the Wilcoxon rank-sum test).
doi:10.1371/journal.pone.0025588.t002
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Modestin and colleagues [47] reported a 14% prevalence rate of
akathisia that was constant over two time points. Janno and colleagues
[19] reported prevalence rates of 31.3% and 27.3%, according to
DSM-IV criteria and the Barnes scale, respectively. In the study by
van Harten and colleagues [32] the reported prevalence of akathisia
was 9.3%. In two retrospective studies in younger patients, neither age
nor sex was related to tardive akathisia [55]. In another study,
particularly younger patients taking higher dosage of (depot)
antipsychotics were at risk of chronic akathisia [56]. In addition,
prevalence of akathisia showed a decreasing trend with age [32].
Tardive dystonia
Van Harten and Kahn [40], reviewing 13 studies, calculated a
mean prevalence of tardive dystonia of 5.3%. Earlier studies tended
to show lower prevalence rates for tardive dystonia than later ones,
probably owing to respectively higher and lower thresholds used,
and to differences in rating scales. Van Harten and colleagues [32]
reported a high prevalence(13.4%) oftardive dystonia;thehigh rate
was thought to relate to the fact that the group examined was black
and/or the fact that a careful standard examination with two
investigators with a comprehensive rating scale was applied. Other
studies reported comparably high prevelances of 11% [57] and
21.6% [58]. Tardive dystonia is evenly distributed across the age of
onset range from 13 to 72 years, and tends to generalize in younger
patients [8]. Patients developing dystonia in isolation tend to be
younger than those with ‘classical’ TD [7].
Van Harten and colleagues [32] found a high prevalence of one
or more types of movement disorders (73.7%). Furthermore, in the
study by Janno and colleagues [19], 61.6% of the patients had at
least one movement disorder according to DSM-IV criteria.
Having persistent drug-induced movement disorders seems to
be the norm for long-stay patients with chronic mental illness and
long-term antipsychotic treatment. We were surprised by the few
notes about these side effects in the files of the patients, which has
been found by others also [28–31]. The relative lack of focus on
movement disorder syndromes is reflected in the very low rate of
DSM-IV axis I diagnosis of these in routine clinical practice.
Several reasons may be responsible for this discrepancy between
clinical reality and clinical attention. First, it is not common
practice to do a systematic investigation toward drug-induced
movement disorders, which will limit recognition. Second,
clinicians may wrongly assume that drug-induced movement
disorders are almost not treatable. In fact, the interventions to
prevent or treat akathisia and parkinsonism are evidence based
and are quite easy to implement in clinical practice. Although
suggested strategies to prevent/treat TD [59] or tardive dystonia
[7] are not evidence-based, they resemble the strategies used to
prevent acute movement disorders. In addition, novel treatment
options are being developed, such as botulinum toxin, tetraben-
azine, branched-chain amino acids, and, in very severe cases, deep
brain stimulation [60–64]. Third, the introduction of the SGAs led
to the expectation that drug-induced movement disorders would
disappear but they only reduce the risk. Furthermore, antipsy-
chotics are increasingly used for other indications as SGAs have
strong mood stabilizing properties which will increase the absolute
numbers of drug-induced movement disorders. Fourth, most
patients with schizophrenia do not complain of their movement
disorder [65–67]. Unawareness of movement disorder and
subsequent lack of subjective complaints is a risk factor for
diagnostic delay [66]. In addition, the unawareness notwithstand-
ing, a movement disorder has a stigmatizing effect on patients and
a negative effect on quality of life. Therefore, active assessment
and treatment of movement disorder, similar to the current
increased focus on metabolic syndrome, is of paramount
importance. Owens [7] stated that movement disorder now can
be seen as a quality-of-care-issue. In addition, shared care decision
making and informed consent is part of antipsychotic treatment
[68]. Systematic diagnosis may help physicians become more
aware of movement disorders.
In conclusion, persistent movement disorder continues to be the
norm for long-stay patients with chronic mental illness requiring
long-term antipsychotic treatment, and therefore measures are
required to remedy this situation, making it part of routine quality-
control procedures. It may be considered somewhat ironic that
long-stay patients with chronic mental illness pay a high price for
the intensive care they receive, particularly because effects are
likely mediated by the relatively high compliance with pharma-
cotherapy in these settings. Although long-stay settings are not
present in abundance anymore, they are also not rare. In the U.S.,
over 200 state hospitals attend a declining but challenging patient
population [69] and the findings likely can be extended to the
considerably larger group of patients who live in supervised
residential settings. Systemic screening for movement disorder
takes little time and can be easily implemented in clinical practice.
In addition, given the clear age dependency of some movement
disorders, elderly patients are a group of special concern.
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